Trial Profile
A study of Brentuximab vedotin in patients with relapsed/refractory Hodgkin's Lymphoma: Hellenic experience
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 29 Mar 2018
Price :
$35
*
At a glance
- Drugs Brentuximab vedotin (Primary)
- Indications Hodgkin's disease
- Focus Therapeutic Use
- 29 Mar 2018 New trial record
- 01 Feb 2018 Results published in the Hematological Oncology